-
Je něco špatně v tomto záznamu ?
Prognostic Accuracy of Three COPD Classification Systems in Relation to Long-Term Mortality of COPD Patients: A Prospective Multicenter Study
M. Plutinsky, K. Brat, M. Svoboda, J. Zatloukal, P. Popelkova, V. Koblizek,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie, práce podpořená grantem
NLK
ProQuest Central
od 2002-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 1997-01-01 do Před 1 rokem
- MeSH
- časové faktory MeSH
- chronická obstrukční plicní nemoc klasifikace diagnóza mortalita terapie MeSH
- databáze faktografické MeSH
- hodnocení rizik MeSH
- kvalita života MeSH
- lidé středního věku MeSH
- lidé MeSH
- metody pro podporu rozhodování * MeSH
- prediktivní hodnota testů MeSH
- prognóza MeSH
- progrese nemoci MeSH
- prospektivní studie MeSH
- rizikové faktory MeSH
- senioři MeSH
- stupeň závažnosti nemoci MeSH
- zdravotní stav MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH
Recent research showed group B patients express higher mortality compared to group C patients when GOLD A-D grouping is used. We aimed to compare the prognostic accuracy of three GOLD classification systems, I-IV ("pre-2011"), A-D ("2011-2016") and A-D ("2017-present") in relation to mortality, exacerbation risk, quality of life (QoL) assessment and specific treatments use in a real-life COPD cohort. We used the data of 720 patients from the Czech Multicenter Research Database of COPD. Four-year mortality and time-to-exacerbation using the GOLD "pre-2011", "2011-2016" and "2017-present" classification schemes were assessed. Moreover, distribution of specific treatments use and QoL measures were analyzed. The GOLD I-IV classification system showed gradual increase in 4-year mortality across the stages (GOLD II 18.8%, III 28.5%, IV 38.7%) (p = 0.001). Using the A-D "2011-2016" classification scheme, group C patients had lower mortality (16.7%) than group B (18.7%) (p = 0.009). The A-D "2017-present" classification showed higher mortality in group B (25.5%) compared to group C (20%) (p = 0.05). For additional outcomes, the GOLD I-IV scheme showed highest match between the calculated 4-year exacerbation risk and QoL measures and GOLD stage/grouping. In terms of specific treatment distributions, various patterns for each GOLD classification system were observed with best match of GOLD "2017-present" system to the layout of GOLD groups and categories. We conclude the GOLD I-IV classification system had the highest accuracy related to mortality, QoL measures and exacerbation risk prediction, while the A-D "2017-present" scheme was most accurate within severity of symptoms prediction reflected also by more frequent specific treatments use.
Institute of Biostatistics and Analyses Ltd Brno Czech Republic
Pulmonary Department University Hospital Ostrava Ostrava Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006616
- 003
- CZ-PrNML
- 005
- 20200522095032.0
- 007
- ta
- 008
- 200511s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00408-019-00196-6 $2 doi
- 035 __
- $a (PubMed)30694380
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Plutinsky, Marek $u Department of Respiratory Diseases, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 62500, Brno, Czech Republic.
- 245 10
- $a Prognostic Accuracy of Three COPD Classification Systems in Relation to Long-Term Mortality of COPD Patients: A Prospective Multicenter Study / $c M. Plutinsky, K. Brat, M. Svoboda, J. Zatloukal, P. Popelkova, V. Koblizek,
- 520 9_
- $a Recent research showed group B patients express higher mortality compared to group C patients when GOLD A-D grouping is used. We aimed to compare the prognostic accuracy of three GOLD classification systems, I-IV ("pre-2011"), A-D ("2011-2016") and A-D ("2017-present") in relation to mortality, exacerbation risk, quality of life (QoL) assessment and specific treatments use in a real-life COPD cohort. We used the data of 720 patients from the Czech Multicenter Research Database of COPD. Four-year mortality and time-to-exacerbation using the GOLD "pre-2011", "2011-2016" and "2017-present" classification schemes were assessed. Moreover, distribution of specific treatments use and QoL measures were analyzed. The GOLD I-IV classification system showed gradual increase in 4-year mortality across the stages (GOLD II 18.8%, III 28.5%, IV 38.7%) (p = 0.001). Using the A-D "2011-2016" classification scheme, group C patients had lower mortality (16.7%) than group B (18.7%) (p = 0.009). The A-D "2017-present" classification showed higher mortality in group B (25.5%) compared to group C (20%) (p = 0.05). For additional outcomes, the GOLD I-IV scheme showed highest match between the calculated 4-year exacerbation risk and QoL measures and GOLD stage/grouping. In terms of specific treatment distributions, various patterns for each GOLD classification system were observed with best match of GOLD "2017-present" system to the layout of GOLD groups and categories. We conclude the GOLD I-IV classification system had the highest accuracy related to mortality, QoL measures and exacerbation risk prediction, while the A-D "2017-present" scheme was most accurate within severity of symptoms prediction reflected also by more frequent specific treatments use.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a databáze faktografické $7 D016208
- 650 12
- $a metody pro podporu rozhodování $7 D003661
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a zdravotní stav $7 D006304
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prediktivní hodnota testů $7 D011237
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a chronická obstrukční plicní nemoc $x klasifikace $x diagnóza $x mortalita $x terapie $7 D029424
- 650 _2
- $a kvalita života $7 D011788
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a časové faktory $7 D013997
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Brat, Kristian $u Department of Respiratory Diseases, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 62500, Brno, Czech Republic. kristian.brat@seznam.cz.
- 700 1_
- $a Svoboda, Michal $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic.
- 700 1_
- $a Zatloukal, Jaromir $u Pulmonary Department, University Hospital Olomouc and Faculty of Medicine, Palacky University, Olomouc, Czech Republic.
- 700 1_
- $a Popelkova, Patrice $u Pulmonary Department, University Hospital Ostrava, Ostrava, Czech Republic.
- 700 1_
- $a Koblizek, Vladimir $u Pulmonary Department, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.
- 773 0_
- $w MED00003159 $t Lung $x 1432-1750 $g Roč. 197, č. 2 (2019), s. 173-179
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30694380 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200522095031 $b ABA008
- 999 __
- $a ok $b bmc $g 1525474 $s 1096672
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 197 $c 2 $d 173-179 $e 20190129 $i 1432-1750 $m Lung $n Lung $x MED00003159
- LZP __
- $a Pubmed-20200511
